Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

according to data from LSEG. Moderna said an independent group determined that a late-stage trial of its cytomegalovirus, or CMV, vaccine did not meet the criteria for early efficacy, but ...

Inflation data, Powell testimony, more earnings will be in focus this week. • Robinhood’s strong financial health, robust ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

In 2023, Moderna initiated a Phase 1/2 study to generate safety and immunogenicity data of an investigational pandemic influenza vaccine (mRNA-1018) in healthy adults aged 18 years and older.

Ward said it would be good to see data from studies of other variant vaccine boosters to compare to the Moderna combination. Expert advisors "must already be thinking about the population at risk ...

Moderna and Merck have reported positive data for mRNA-4157 in a phase 2 melanoma trial, and we assume a 60% probability of success and multi-billion-dollar sales potential, with even higher ...

A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

Next-generation COVID-19 vaccine: Moderna shared positive Phase 3 vaccine efficacy and immunogenicity data for its next-generation COVID-19 vaccine (mRNA-1283) at its 2024 R&D Day event.